查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863450

下一代生物製造市場按產品類型、技術、製程步驟、最終用戶、營運規模、細胞株和製程模式分類－2025-2032年全球預測

Next-Generation Biomanufacturing Market by Product Type, Technology, Process Stage, End User, Operation Scale, Cell Line, Process Mode - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，下一代生物製造市場將成長至 424.3 億美元，複合年成長率為 9.38%。

主要市場統計數據
基準年 2024 206.9億美元
預計年份：2025年 226.6億美元
預測年份：2032年 424.3億美元
複合年成長率 (%) 9.38%

這是一部權威性的介紹性著作，它將下一代生物製造定位在先進生技藥品開發、模組化生產架構、勞動力戰略和全球供應鏈韌性的交匯點上。

下一代生物製造正成為未來十年最重要的產業變革之一，其驅動力來自生技藥品的快速發展、靈活的生產技術以及疫情時代建構韌性供應鏈的需求。這項公告不僅將該領域定位為現有製造能力的演進，更是療法發現、生產和交付方式的系統性轉變。在整個開發平臺中，研發人員正在開發日益複雜的治療方法，包括細胞和基因療法、重組蛋白、單株抗體和新型疫苗平台，這推動了對能夠同時支持小規模批量個人化治療和大規模商業供應的生產架構的需求。

變革性技術創新、監管調整和商業性模式轉變如何在全球範圍內重新定義生物製造能力、工藝架構、資本配置和策略性投資

生物製造格局正因技術創新、法規演變和商業策略交會處的多重變革而重塑。首先，科技融合正在加速。連續生物製程和先進分析技術正與一次性硬體和模組化設施設計相融合，從而建構出既靈活又高度自動化的系統。這種融合縮短了技術轉移週期，減少了等待時間，並實現了更可預測的品質特性。隨著製程的成熟，這些因素共同降低了營運複雜性。

評估2025年美國關稅對生物製造生態系中原物料採購、契約製造經濟、跨境供應鏈、資本配置和近岸外包決策的累積影響

2025年美國關稅政策對生物製造生態系統產生了複雜且累積的影響，其影響遠不止於即時的成本上漲。最初，關稅提高了進口原料、一次性零件和專用設備的到岸成本，促使採購部門重新評估其供應商組合和合約條款。隨著時間的推移，這些更高的投入成本可能會改變採購節奏，促使企業進行大量採購並簽署長期供應協議，以對沖關稅波動風險。因此，採購策略正從現貨採購轉向能夠提供價格穩定和技術合作的策略合作關係。

關鍵細分洞察揭示了產品類型、底層技術、各個製程步驟、各類終端用戶、營運規模、細胞株選擇和製程模式等因素如何決定產能投資和商業化策略。

精細化的細分框架明確了在產品類型、技術、製程階段、最終用戶、營運規模、細胞株和製程模式等方面，產能投資和策略重點應如何才能最有效地發揮作用。縱觀各類產品，細胞和基因療法（包括CAR-T療法、細胞療法和基因編輯療法）需要獨特​​的生產模式，對小規模批量生產和患者特異性生產物流有著高度的敏感性。酶的應用涵蓋診斷和工業領域，這些應用場景優先考慮的是通量和成本效益。單株抗體根據自體免疫、感染疾病和腫瘤治療的不同而有所差異，每種應用對效力和純度的要求也各不相同。重組蛋白（包括細胞激素、生長因子和荷爾蒙）通常需要嚴格控制上游和下游工作流程。疫苗涵蓋多種平台，包括減毒活病毒疫苗、mRNA疫苗、次單位疫苗和病毒載體疫苗，每個平台都對低溫運輸和灌裝包裝製程提出了不同的要求。

美洲、歐洲、中東和非洲以及亞太地區生物製造領導者面臨的區域趨勢和戰略影響，這些趨勢和戰略影響將波及生產位置、監管協調、人才流動和跨境合作。

區域趨勢對企業的策略決策至關重要，因為它們決定了生產位置、供應鏈架構以及監管管道的優先順序。在美洲，完善的臨床生態系統、強勁的投資者興趣和密集的供應商網路共同推動了快速商業化和個人化療法利基製造的發展。然而，供應鏈摩擦和政策不確定性仍可能導致選擇性近岸外包和供應商選擇更加嚴格。在歐洲、中東和非洲，監管協調工作和強大的公私合營為大規模生物製藥和疫苗生產創造了極具吸引力的地點。然而，區域監管差異需要製定針對特定區域的申報策略，並需要較長的市場准入時間。

企業級洞察，展現製藥開發商、契約製造製造商、技術提供商和系統整合商如何重組其產品組合、建立策略聯盟並最佳化其製造地，以抓住機會。

生物製造價值鏈中的主要企業正透過產能擴張、策略聯盟和有針對性地採用新技術等方式適應不斷變化的市場環境。為了獲得更大價值並加快客戶產品上市速度，契約製造正在擴展其整合服務範圍，涵蓋細胞庫建置、分析開發以及商業規模的填充和包裝。技術供應商則專注於模組化、一次性產品和數位化平台，以實現遠端監控和預測性維護，從而降低營運風險並促進多地點協作。製藥開發商則透過保留對細胞株開發和製程表徵等關鍵流程的策略控制權，同時將常規的放大生產和大規模生產外包給專業合作夥伴，從​​而實現差異化競爭優勢。

為行業領導者提供切實可行的策略建議，以加速採用先進生物製程，確保供應鏈的韌性，使商業模式與不斷變化的法規保持一致，並優先考慮可擴展的投資以獲得長期優勢。

在技​​術和政策快速變革的背景下，行業領導者應採取務實且優先的行動，以獲得競爭優勢。首先，加速採用模組化、一次性資產，用於早期靈活的商業化生產，以縮短實施時間並減輕驗證負擔。這種方法允許在有限的資本預算內引入創新製程模式，例如灌注和連續層析法，並在產品經濟效益證明值得進行大規模固定投資時，選擇性地擴大生產規模。其次，加強供應商多元化和策略採購協議，以降低關稅相關的成本波動，並最大限度地減少單一供應商失效的風險。同時，制定緊急時應對計畫，其中包括本地製造合作夥伴和檢驗的二級供應商。

我們透明的調查方法詳細說明了整合的一手和二手研究、專家訪談、數據三角驗證、檢驗過程、細分映射和可複製的評估技術，以產生可靠的市場洞察。

本分析的調查方法採用綜合方法，結合一手訪談、二手文獻整合和嚴謹的三角驗證，以確保研究結果的穩健性和可重複性。一手研究包括對研發、製造、採購和監管事務等部門的高級管理人員進行結構化訪談，以及與技術供應商、系統整合商和契約製造製造商進行深入交流。這些工作揭示了技術轉移和規模化生產的實際限制、投資重點和案例研究。二手研究涵蓋了同行評審文獻、公開監管指導文件和技術白皮書，以闡明發展趨勢並檢驗技術論點。

簡明扼要的策略結論，整合了關鍵要點、風險緩解需求、投資重點和前瞻性考量，旨在幫助相關人員在下一代生物製造領域確立主導。

總之，下一代生物製藥標誌著一個策略轉折點，技術創新、供應鏈策略和監管調整正在融合，重塑產業的經濟格局和競爭動態。連續生物製程、模組化設施、一次性系統和數位分析技術的成熟，為更快、更可靠地生產複雜生物製藥鋪平了道路，但要實現這些優勢，需要對能力和夥伴關係關係進行有意識的投資。因此，領導者必須使資本配置與特定製劑的需求相匹配，優先考慮供應商在面對地緣政治和關稅衝擊時的韌性，並組建能夠管理自動化、數據驅動型營運的跨職能團隊。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合一次性反應器系統以加速靈活生物製造能力的發展
  • 利用 CRISPR 基因編輯平台最佳化微生物細胞工廠，實現產量蛋白質療法藥物的生產
  • 採用連續灌註生物加工技術可提高產品均勻性並降低成本。
  • 部署人工智慧驅動的數位雙胞胎，實現即時過程監控和預測性生物過程控制
  • 開發用於細胞株性能高通量篩檢的模組化微流體平台
  • 將可生物分解奈米材料應用於精準生物醫藥製造中的標靶藥物遞送
  • 利用木質纖維素生質能作為永續原料，透過微生物發酵生產生物基化學品
  • 擴大無細胞蛋白合成系統的規模，以便在照護端快速、按需生產生技藥品
  • 利用mRNA-脂質奈米顆粒技術在分散式生產網路中擴大疫苗生產規模
  • 透過協調先進治療藥物的監管，加速全球生物製藥核准

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按產品類型分類的下一代生物製造市場

  • 細胞和基因治療
    • CAR-T療法
    • 細胞療法
    • 基因編輯療法
  • 酵素
    • 診斷酶
    • 工業酵素
  • 單株抗體
    • 自體免疫疾病
    • 感染疾病
    • 腫瘤學
  • 重組蛋白
    • 細胞激素
    • 生長因子
    • 荷爾蒙
  • 疫苗
    • 減毒活病毒疫苗
    • mRNA疫苗
    • 次單位疫苗
    • 病毒載體疫苗

第9章：按技術分類的下一代生物製造市場

  • 無細胞系統
    • 無細胞表現試劑盒
    • 無細胞合成平台
  • 連續生物程序
    • 連續層析法
    • 在線連續監測系統
    • 灌注系統
  • 模組化設施
    • 預製模組
    • 滑橇式安裝系統
  • 免洗系統
    • 免洗袋子
    • 免洗生物反應反應器
    • 一次性軟管和接頭

第10章：按製程階段分類的下一代生物製造市場

  • 下游工藝
    • 層析法
    • 濾
    • 純化
  • 配方
    • 填充和精加工
    • 冷凍乾燥
    • 包裝
  • 上游工藝
    • 反應器運行
    • 細胞培養
    • 培養基製備

第11章：按最終用戶分類的下一代生物製造市場

  • 學術和研究機構
  • 生技公司
  • 契約製造組織
  • 製藥公司

第12章：按營運規模分類的下一代生物製造市場

  • 臨床量表
  • 商業規模
  • 中試規模

第13章：按細胞株的下一代生物製造市場

  • Cho 細胞
    • Cho-DG44
    • Cho-K1
  • 大腸桿菌
    • BL21
    • K12
  • 酵母菌
    • 畢赤酵母
    • 釀酒酵母

第14章：以製程模式分類的下一代生物製造市場

  • 批次
  • 連續型
  • 連續培養法
  • 灌注

第15章：按地區分類的下一代生物製造市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：按群體分類的下一代生物製造市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：各國下一代生物製造市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novozymes A/S
    • Koninklijke DSM NV
    • Evonik Industries AG
    • Ginkgo Bioworks Holdings, Inc.
    • Amyris, Inc.
    • Codexis, Inc.
    • Zymergen Inc.
    • Genomatica, Inc.
    • Evolva Holding SA
    • LanzaTech, Inc.
Product Code: MRR-5C6F41F5AFEF

The Next-Generation Biomanufacturing Market is projected to grow by USD 42.43 billion at a CAGR of 9.38% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 20.69 billion
Estimated Year [2025] USD 22.66 billion
Forecast Year [2032] USD 42.43 billion
CAGR (%) 9.38%

An authoritative introduction positioning next-generation biomanufacturing at the intersection of advanced biologics development, modular production architectures, workforce talent strategies, and global supply resilience

Next-generation biomanufacturing is emerging as one of the most consequential industrial transformations of the coming decade, propelled by rapid advances in biologics, flexible production technologies, and a post-pandemic imperative for resilient supply chains. This introduction frames the sector not merely as an evolution of existing manufacturing capabilities but as a systemic shift in how therapeutics are discovered, produced, and delivered. Across development pipelines, developers are pursuing increasingly complex modalities including cell and gene therapies, recombinant proteins, monoclonal antibodies, and novel vaccine platforms, driving demand for production architectures that can support small-batch personalization and scalable commercial supply concurrently.

Moreover, new manufacturing paradigms-such as modular facilities, single-use systems, continuous bioprocessing, and cell-free technologies-are enabling faster time-to-clinic, reduced capital intensity for initial capacity, and improved responsiveness to demand variability. Consequently, operational priorities now include rapid technology transfer, enhanced process analytics for inline monitoring, and workforce upskilling to manage programmable, highly automated operations. As stakeholders evaluate strategic options, this report positions the industry's trajectory in terms of capability buildout, competitive dynamics among developers and contract manufacturers, and the policy environments influencing cross-border supply. In doing so, it provides a structured foundation for leaders seeking to balance innovation speed, manufacturing reliability, and regulatory compliance.

How transformative technological innovations, regulatory recalibrations, and commercial shifts are collectively redefining biomanufacturing capacity, process architectures, capital allocation, and strategic investments worldwide

The landscape of biomanufacturing is being reshaped by several transformative shifts that intersect technological innovation, regulatory evolution, and commercial strategy. First, technological convergence is accelerating: continuous bioprocessing and advanced analytics are merging with single-use hardware and modular facility designs to produce systems that are both flexible and highly automated. This convergence shortens technology transfer cycles, reduces hold times, and enables more predictable quality attributes, which collectively lower operational complexity as processes mature.

Second, regulatory pathways are adapting to accommodate novel modalities and decentralized production models. In turn, regulators are placing greater emphasis on real-time release testing, risk-based validation approaches, and harmonization efforts that reduce duplication across markets. As a result, manufacturers that proactively invest in robust process characterization and digital quality architectures are increasingly positioned to gain regulatory latitude and accelerate time-to-patient.

Third, commercial models are evolving in response to demand fragmentation and premium pricing dynamics for personalized therapies. Contract development and manufacturing organizations will therefore take on greater responsibility for end-to-end program delivery, including integrated analytics, cell banking, and cold-chain logistics orchestration. Finally, strategic capital allocation is shifting toward platforms that offer rapid scalability-prefabricated modules and skid-mounted systems-enabling companies to respond to therapeutic breakthroughs and regional demand shifts with lower up-front risk. Together, these shifts are not isolated; they interact to create a new operational logic where speed, quality, and adaptability determine competitive advantage.

Assessing the cumulative effects of United States tariff actions in 2025 on raw material sourcing, contract manufacturing economics, cross-border supply chains, capital deployment, and nearshoring decisions across biomanufacturing ecosystems

United States tariff actions in 2025 have imposed a complex, cumulative set of effects across the biomanufacturing ecosystem, with implications that extend beyond immediate cost inflation. Initially, tariffs increase the landed cost of imported raw materials, single-use components, and specialized instrumentation, prompting sourcing teams to reassess supplier portfolios and contractual terms. Over time, those higher input costs alter procurement rhythms and may incentivize bulk purchasing or long-term supply agreements to hedge against tariff volatility. As a result, purchasing strategies are shifting from spot buys toward strategic relationships that offer price stability and technical collaboration.

In addition to direct cost impacts, tariffs reshape strategic decisions around localization and capacity siting. Facing persistent tariff risk, some organizations accelerate nearshoring or onshoring initiatives to reduce exposure to cross-border duties and to shorten supply chains. This movement influences capital deployment, as companies weigh the trade-offs between the higher initial capital required for localized facilities and the operational benefits of reduced border friction, shorter lead times, and improved control over quality-critical inputs. Conversely, regions that maintain open trade policies and competitive supplier ecosystems can attract outsourced production and enable multinational companies to centralize specialized manufacturing tasks.

Tariffs also interact with regulatory and logistical dynamics. Increased customs inspections and documentation requirements extend lead times for critical materials, amplifying the need for higher safety stock levels and more granular inventory management. Moreover, the cumulative effect of tariffs on specialized consumables and single-use components can accelerate investment in alternative technologies such as reusable bioreactors or local fabrication of ancillary equipment, where feasible. In sum, the 2025 tariff environment compels a more strategic orientation toward supplier diversification, resilience planning, and the re-evaluation of global footprint strategies for biomanufacturing stakeholders.

Key segmentation insights revealing how nuanced product types, enabling technologies, discrete process stages, varied end users, operational scales, cell line selections, and process modes determine capability investments and commercialization strategies

A nuanced segmentation framework clarifies where capability investments and strategic emphasis will be most consequential across product types, technologies, process stages, end users, operational scales, cell lines, and process modes. When looking across product types, cell and gene therapies demand unique manufacturing paradigms that include CAR-T therapies, cell therapies, and gene editing therapies with high sensitivity to small-batch, patient-specific production logistics, whereas enzymes span diagnostic and industrial use cases that prioritize throughput and cost efficiency. Monoclonal antibodies fragment into autoimmune, infectious disease, and oncology applications with divergent potency and purity needs. Recombinant proteins, including cytokines, growth factors, and hormones, typically require tightly controlled upstream and downstream workflows. Vaccines encompass a spectrum of platforms-live attenuated, mRNA, subunit, and viral vector vaccines-each of which imposes distinct cold-chain and fill-finish constraints.

Technological segmentation further underscores differences in capital allocation and operational design. Cell-free systems, whether sold as expression kits or integrated synthesis platforms, introduce options for decentralized manufacturing and rapid prototyping. Continuous bioprocessing elements-such as continuous chromatography, inline monitoring systems, and perfusion technologies-enable steady-state operations that reduce batch-to-batch variability. Modular facilities built from prefabricated modules or skid-mounted systems deliver faster commissioning, while single-use systems comprised of single-use bags, bioreactors, and tubing reduce cleaning validation burdens and cross-contamination risk. Process stage segmentation clarifies where value is created: upstream processing activities like bioreactor operation, cell culture, and media preparation set biological performance, while downstream processing through chromatography, filtration, and purification, together with formulation activities such as fill-and-finish, lyophilization, and packaging, determine final product stability and patient readiness.

End-user segmentation differentiates academic and research institutions, biotech companies, contract manufacturing organizations, and pharmaceutical companies as distinct decision-makers with varied priorities. Operation scale separates clinical, pilot, and commercial stages, each with its own tolerance for risk and capital intensity. Cell line choice-CHO cell variants like CHO-DG44 and CHO-K1, E. coli strains such as BL21 and K12, and yeast species including Pichia pastoris and Saccharomyces cerevisiae-influences expression yield, glycosylation profiles, and downstream purification strategies. Finally, process mode selection among batch, continuous, fed-batch, and perfusion determines facility layout, analytics needs, and staffing models. Integrating these segmentation lenses helps executives prioritize investments that align with modality-specific technical constraints and commercial trajectories.

Regional dynamics and strategic implications across the Americas, Europe Middle East and Africa, and Asia-Pacific that influence capacity siting, regulatory harmonization, talent migration, and cross-border collaboration for biomanufacturing leaders

Regional dynamics are central to strategic decision-making as companies decide where to locate capacity, how to structure supply chains, and which regulatory pathways to prioritize. In the Americas, the combination of advanced clinical ecosystems, robust investor interest, and a dense supplier network supports rapid commercialization and the growth of niche manufacturing for personalized therapies; however, supply-chain friction and policy uncertainty can still drive selective nearshoring and stronger vendor qualification efforts. In Europe, Middle East & Africa, regulatory harmonization efforts and strong public-private collaborations are creating attractive hubs for large-volume biologics and vaccine manufacturing, although localized regulatory nuances require region-specific dossier strategies and extended timelines for market entry.

Asia-Pacific presents a bifurcated landscape where mature markets sustain high-quality contract manufacturing capacity and emerging markets accelerate investments in local production to ensure sovereign supply for essential biologics and vaccines. Across all regions, cross-border collaboration remains essential, as technology providers, contract manufacturers, and developers form transnational partnerships to optimize cost, access specialist skills, and achieve scale. Talent flows, regulatory convergence, and infrastructure investments-such as logistics corridors and cold-chain networks-will therefore determine which regions become centers of excellence for particular modalities. Importantly, companies that align their footprint strategy with local incentives, skilled labor pools, and supply ecosystems will be better positioned to manage regulatory complexity and reduce time-to-clinic across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Company-level insights highlighting how pharmaceutical developers, contract manufacturers, technology providers, and system integrators are reshaping portfolios, forming strategic alliances, and optimizing manufacturing footprints to capture opportunity

Leading companies across the biomanufacturing value chain are responding to the evolving landscape by pursuing a mix of capability expansion, strategic partnerships, and targeted technology adoption. Contract manufacturing organizations are increasingly offering integrated services that span cell banking, analytical development, and commercial-scale fill-finish in order to capture greater value and reduce client time to market. Technology providers are focusing on modularization, single-use content, and digital platforms that enable remote monitoring and predictive maintenance, thereby lowering operational risk and supporting multi-site orchestration. Pharmaceutical developers are differentiating by retaining strategic control over critical steps-such as cell line development and process characterization-while outsourcing routine scale-up and high-volume production to specialized partners.

Across the ecosystem, strategic alliances and co-investment models are proliferating as a way to share development risk and accelerate access to capacity. Companies are also prioritizing investments in advanced analytics and automation to reduce batch variability, improve yield, and accelerate regulatory approvals. Talent strategies have become a point of competitive differentiation, with firms investing in cross-disciplinary training programs to bridge gaps between process development, data science, and quality assurance. Finally, corporate governance around supply resilience is evolving: executive teams now require scenario planning for tariff shocks, supplier disruptions, and rapid demand surges, and they increasingly expect portfolio managers to demonstrate supply continuity plans as part of go/no-go commercialization decisions.

Actionable strategic recommendations for industry leaders to accelerate adoption of advanced bioprocessing, secure resilient supply networks, align commercial models with regulatory evolutions, and prioritize scalable investments for long-term advantage

Industry leaders should take pragmatic, prioritized actions to secure advantage amid rapid technological and policy change. First, accelerate deployment of modular and single-use assets for early-stage and flexible commercial production to reduce time-to-deploy and lower validation overhead. This approach allows organizations to pilot innovative process modes such as perfusion or continuous chromatography within a constrained capital envelope, and then scale selectively as product economics justify larger fixed investments. Second, enhance supplier diversification and strategic sourcing agreements to mitigate tariff-related cost inflections and minimize the risk of single-source failures; in parallel, develop contingency plans that include local fabrication partners and validated secondary suppliers.

Third, invest in digital quality and process analytics to support real-time release strategies and to satisfy evolving regulatory expectations. Such capabilities shorten approval timelines and enable more efficient tech transfer across sites. Fourth, cultivate workforce resilience through structured cross-training programs that integrate process science, automation skills, and data literacy, ensuring teams can operate highly automated, multi-site networks. Fifth, adopt a selective nearshoring framework that evaluates total landed cost, regulatory alignment, and lead-time reduction benefits versus capital outlay. Finally, pursue collaborative models with academic centers and technology providers to stay at the leading edge of modalities such as cell-free systems and mRNA platforms; by doing so, leaders can capture first-mover advantages while distributing technical risk.

Transparent research methodology detailing integrated primary and secondary research, expert interviews, data triangulation, validation processes, segmentation mapping, and reproducible assessment techniques for robust market insight generation

The research methodology underpinning this analysis draws on an integrated approach that combines primary interviews, secondary literature synthesis, and rigorous triangulation to ensure robustness and reproducibility. Primary research included structured interviews with senior executives across development, manufacturing, procurement, and regulatory functions, alongside in-depth conversations with technology vendors, system integrators, and contract manufacturers. These engagements surfaced practical constraints, investment priorities, and real-world examples of technology transfer and scaling challenges. Secondary research encompassed peer-reviewed literature, public regulatory guidance documents, and technical white papers to contextualize trends and to validate technical assertions.

Data triangulation was applied to reconcile insights across sources: qualitative interview data were cross-referenced with technical specifications, procurement practices, and regulatory guidance to identify convergent themes. Segmentation logic was iteratively validated with subject-matter experts to ensure that product types, technology classes, process stages, end-user categories, operation scales, cell lines, and process modes reflect industry realities and purchasing behaviors. Finally, the methodology incorporated scenario analysis to explore how tariff shocks, supply disruptions, and rapid adoption of new process technologies could affect strategic choices. Where applicable, methodological limitations and areas for further research are documented to guide readers in interpreting the findings and applying them within their own organizational contexts.

A concise strategic conclusion synthesizing critical takeaways, risk-mitigation imperatives, investment priorities, and forward-looking considerations for stakeholders seeking to lead in next-generation biomanufacturing

In conclusion, next-generation biomanufacturing represents a strategic inflection point where technological innovation, supply-chain strategy, and regulatory adaptation converge to reshape industry economics and competitive dynamics. The maturation of continuous bioprocessing, modular facilities, single-use systems, and digital analytics creates a pathway for faster, more reliable production of complex biologics, but realizing these benefits requires intentional investment in capabilities and partnerships. Leaders must therefore align capital allocation with modality-specific needs, prioritize supplier resilience in the face of geopolitical and tariff-induced disruptions, and build cross-functional teams capable of managing automated, data-rich operations.

Looking ahead, the organizations that will succeed are those that adopt a systems view-integrating process development, regulatory strategy, and commercial planning-and that remain agile in their footprint decisions. The imperative is not only to adopt new technologies but to embed them within governance frameworks that ensure quality, reproducibility, and rapid scale-up. By combining targeted investments in flexible infrastructure, strategic supplier relationships, and workforce development, stakeholders can navigate uncertainty and capture the transformative potential of next-generation biomanufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of single-use bioreactor systems to accelerate flexible biomanufacturing capacity
  • 5.2. Utilization of CRISPR gene editing platforms to optimize microbial cell factories for high-yield protein therapeutics
  • 5.3. Adoption of continuous perfusion bioprocessing techniques to improve product consistency and reduce costs
  • 5.4. Implementation of AI-driven digital twins for real-time process monitoring and predictive bioprocess control
  • 5.5. Development of modular microfluidic platforms for high-throughput screening of cell line performance
  • 5.6. Incorporation of biodegradable nanomaterials for targeted drug delivery in precision biomedicine manufacturing
  • 5.7. Sustainable feedstock sourcing from lignocellulosic biomass for microbial fermentation to produce bio-based chemicals
  • 5.8. Expansion of cell-free protein synthesis systems for rapid on-demand biologics production at point of care
  • 5.9. Scale-up of vaccine manufacturing using mRNA lipid nanoparticle technologies across distributed production networks
  • 5.10. Regulatory harmonization for advanced therapy medicinal products to accelerate global biomanufacturing approvals

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Biomanufacturing Market, by Product Type

  • 8.1. Cell And Gene Therapies
    • 8.1.1. Car-T Therapies
    • 8.1.2. Cell Therapies
    • 8.1.3. Gene Editing Therapies
  • 8.2. Enzymes
    • 8.2.1. Diagnostic Enzymes
    • 8.2.2. Industrial Enzymes
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Autoimmune
    • 8.3.2. Infectious Diseases
    • 8.3.3. Oncology
  • 8.4. Recombinant Proteins
    • 8.4.1. Cytokines
    • 8.4.2. Growth Factors
    • 8.4.3. Hormones
  • 8.5. Vaccines
    • 8.5.1. Live Attenuated Vaccines
    • 8.5.2. Mrna Vaccines
    • 8.5.3. Subunit Vaccines
    • 8.5.4. Viral Vector Vaccines

9. Next-Generation Biomanufacturing Market, by Technology

  • 9.1. Cell-Free Systems
    • 9.1.1. Cell-Free Expression Kits
    • 9.1.2. Cell-Free Synthesis Platforms
  • 9.2. Continuous Bioprocessing
    • 9.2.1. Continuous Chromatography
    • 9.2.2. Inline Monitoring Systems
    • 9.2.3. Perfusion Systems
  • 9.3. Modular Facilities
    • 9.3.1. Prefabricated Modules
    • 9.3.2. Skid-Mounted Systems
  • 9.4. Single-Use Systems
    • 9.4.1. Single-Use Bags
    • 9.4.2. Single-Use Bioreactors
    • 9.4.3. Single-Use Tubing And Connectors

10. Next-Generation Biomanufacturing Market, by Process Stage

  • 10.1. Downstream Processing
    • 10.1.1. Chromatography
    • 10.1.2. Filtration
    • 10.1.3. Purification
  • 10.2. Formulation
    • 10.2.1. Fill And Finish
    • 10.2.2. Lyophilization
    • 10.2.3. Packaging
  • 10.3. Upstream Processing
    • 10.3.1. Bioreactor Operation
    • 10.3.2. Cell Culture
    • 10.3.3. Media Preparation

11. Next-Generation Biomanufacturing Market, by End User

  • 11.1. Academic And Research Institutions
  • 11.2. Biotech Companies
  • 11.3. Contract Manufacturing Organizations
  • 11.4. Pharmaceutical Companies

12. Next-Generation Biomanufacturing Market, by Operation Scale

  • 12.1. Clinical Scale
  • 12.2. Commercial Scale
  • 12.3. Pilot Scale

13. Next-Generation Biomanufacturing Market, by Cell Line

  • 13.1. Cho Cell
    • 13.1.1. Cho-DG44
    • 13.1.2. Cho-K1
  • 13.2. E. Coli
    • 13.2.1. Bl21
    • 13.2.2. K12
  • 13.3. Yeast
    • 13.3.1. Pichia Pastoris
    • 13.3.2. Saccharomyces Cerevisiae

14. Next-Generation Biomanufacturing Market, by Process Mode

  • 14.1. Batch
  • 14.2. Continuous
  • 14.3. Fed Batch
  • 14.4. Perfusion

15. Next-Generation Biomanufacturing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Next-Generation Biomanufacturing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Next-Generation Biomanufacturing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Novozymes A/S
    • 18.3.2. Koninklijke DSM N.V.
    • 18.3.3. Evonik Industries AG
    • 18.3.4. Ginkgo Bioworks Holdings, Inc.
    • 18.3.5. Amyris, Inc.
    • 18.3.6. Codexis, Inc.
    • 18.3.7. Zymergen Inc.
    • 18.3.8. Genomatica, Inc.
    • 18.3.9. Evolva Holding SA
    • 18.3.10. LanzaTech, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY OPERATION SCALE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY OPERATION SCALE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL LINE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS MODE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NEXT-GENERATION BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. NEXT-GENERATION BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION BIOMANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LYOPHILIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LYOPHILIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LYOPHILIZATION, BY GROUP, 2018-2024 (USD MILLION)

TABLE 27